nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—uterine cancer	0.412	0.818	CbGbCtD
Orlistat—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0425	0.0843	CbGbCtD
Orlistat—CYP3A4—Progesterone—uterine cancer	0.0281	0.0558	CbGbCtD
Orlistat—CYP3A4—Etoposide—uterine cancer	0.0126	0.025	CbGbCtD
Orlistat—PNLIP—exocrine gland—uterine cancer	0.01	0.0625	CbGeAlD
Orlistat—CYP3A4—Doxorubicin—uterine cancer	0.00859	0.017	CbGbCtD
Orlistat—PLA2G7—myometrium—uterine cancer	0.00631	0.0394	CbGeAlD
Orlistat—ABHD16A—myometrium—uterine cancer	0.00592	0.037	CbGeAlD
Orlistat—DAGLB—decidua—uterine cancer	0.00579	0.0362	CbGeAlD
Orlistat—ABHD12—myometrium—uterine cancer	0.00555	0.0347	CbGeAlD
Orlistat—PLA2G7—decidua—uterine cancer	0.00468	0.0292	CbGeAlD
Orlistat—FASN—myometrium—uterine cancer	0.00466	0.0291	CbGeAlD
Orlistat—ABHD16A—uterine cervix—uterine cancer	0.00461	0.0288	CbGeAlD
Orlistat—PLA2G7—endometrium—uterine cancer	0.00444	0.0278	CbGeAlD
Orlistat—ABHD16A—decidua—uterine cancer	0.00439	0.0274	CbGeAlD
Orlistat—ABHD12—uterine cervix—uterine cancer	0.00432	0.027	CbGeAlD
Orlistat—PLA2G7—mammalian vulva—uterine cancer	0.0043	0.0268	CbGeAlD
Orlistat—ABHD16A—endometrium—uterine cancer	0.00417	0.026	CbGeAlD
Orlistat—DAGLB—female gonad—uterine cancer	0.00415	0.0259	CbGeAlD
Orlistat—ABHD12—decidua—uterine cancer	0.00411	0.0257	CbGeAlD
Orlistat—ABHD16A—mammalian vulva—uterine cancer	0.00403	0.0252	CbGeAlD
Orlistat—ABHD12—endometrium—uterine cancer	0.00391	0.0244	CbGeAlD
Orlistat—ABHD12—mammalian vulva—uterine cancer	0.00378	0.0236	CbGeAlD
Orlistat—FASN—uterine cervix—uterine cancer	0.00362	0.0226	CbGeAlD
Orlistat—FASN—decidua—uterine cancer	0.00345	0.0216	CbGeAlD
Orlistat—PLA2G7—female gonad—uterine cancer	0.00335	0.0209	CbGeAlD
Orlistat—PLA2G7—vagina—uterine cancer	0.00333	0.0208	CbGeAlD
Orlistat—PNLIP—female reproductive system—uterine cancer	0.00324	0.0202	CbGeAlD
Orlistat—FASN—mammalian vulva—uterine cancer	0.00317	0.0198	CbGeAlD
Orlistat—ABHD16A—female gonad—uterine cancer	0.00314	0.0196	CbGeAlD
Orlistat—ABHD16A—vagina—uterine cancer	0.00312	0.0195	CbGeAlD
Orlistat—FASN—uterus—uterine cancer	0.00302	0.0189	CbGeAlD
Orlistat—ABHD12—female gonad—uterine cancer	0.00294	0.0184	CbGeAlD
Orlistat—PNLIP—female gonad—uterine cancer	0.00294	0.0184	CbGeAlD
Orlistat—ABHD12—vagina—uterine cancer	0.00293	0.0183	CbGeAlD
Orlistat—DAGLB—lymph node—uterine cancer	0.00267	0.0167	CbGeAlD
Orlistat—FASN—female gonad—uterine cancer	0.00247	0.0154	CbGeAlD
Orlistat—FASN—vagina—uterine cancer	0.00246	0.0153	CbGeAlD
Orlistat—PLA2G4A—myometrium—uterine cancer	0.00224	0.014	CbGeAlD
Orlistat—PLA2G7—lymph node—uterine cancer	0.00215	0.0134	CbGeAlD
Orlistat—ABHD16A—lymph node—uterine cancer	0.00202	0.0126	CbGeAlD
Orlistat—ABHD12—lymph node—uterine cancer	0.00189	0.0118	CbGeAlD
Orlistat—PLA2G4A—uterine cervix—uterine cancer	0.00174	0.0109	CbGeAlD
Orlistat—PLA2G4A—smooth muscle tissue—uterine cancer	0.00169	0.0106	CbGeAlD
Orlistat—PLA2G4A—decidua—uterine cancer	0.00166	0.0104	CbGeAlD
Orlistat—PLA2G4A—renal system—uterine cancer	0.00163	0.0102	CbGeAlD
Orlistat—FASN—lymph node—uterine cancer	0.00159	0.00992	CbGeAlD
Orlistat—PLA2G4A—endometrium—uterine cancer	0.00158	0.00984	CbGeAlD
Orlistat—PLA2G4A—mammalian vulva—uterine cancer	0.00152	0.00952	CbGeAlD
Orlistat—PLA2G4A—female reproductive system—uterine cancer	0.00131	0.00815	CbGeAlD
Orlistat—PLA2G4A—female gonad—uterine cancer	0.00119	0.00742	CbGeAlD
Orlistat—PLA2G4A—vagina—uterine cancer	0.00118	0.00737	CbGeAlD
Orlistat—PLA2G4A—lymph node—uterine cancer	0.000764	0.00477	CbGeAlD
Orlistat—CYP3A4—renal system—uterine cancer	0.000538	0.00336	CbGeAlD
Orlistat—CYP3A4—female reproductive system—uterine cancer	0.000431	0.00269	CbGeAlD
Orlistat—Eructation—Doxorubicin—uterine cancer	0.000336	0.00145	CcSEcCtD
Orlistat—Discomfort—Dactinomycin—uterine cancer	0.000335	0.00145	CcSEcCtD
Orlistat—Neoplasm—Epirubicin—uterine cancer	0.000334	0.00144	CcSEcCtD
Orlistat—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000331	0.00143	CcSEcCtD
Orlistat—Asthenia—Progesterone—uterine cancer	0.00033	0.00143	CcSEcCtD
Orlistat—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00033	0.00142	CcSEcCtD
Orlistat—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00033	0.00142	CcSEcCtD
Orlistat—Urinary tract disorder—Etoposide—uterine cancer	0.000327	0.00141	CcSEcCtD
Orlistat—Pruritus—Progesterone—uterine cancer	0.000326	0.00141	CcSEcCtD
Orlistat—Oedema—Dactinomycin—uterine cancer	0.000325	0.0014	CcSEcCtD
Orlistat—Urethral disorder—Etoposide—uterine cancer	0.000325	0.0014	CcSEcCtD
Orlistat—Infection—Dactinomycin—uterine cancer	0.000323	0.00139	CcSEcCtD
Orlistat—Vaginal infection—Doxorubicin—uterine cancer	0.000323	0.00139	CcSEcCtD
Orlistat—Diarrhoea—Progesterone—uterine cancer	0.000315	0.00136	CcSEcCtD
Orlistat—Cramps of lower extremities—Doxorubicin—uterine cancer	0.000314	0.00136	CcSEcCtD
Orlistat—Neoplasm—Doxorubicin—uterine cancer	0.000309	0.00134	CcSEcCtD
Orlistat—Diabetes mellitus—Epirubicin—uterine cancer	0.000309	0.00133	CcSEcCtD
Orlistat—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000307	0.00133	CcSEcCtD
Orlistat—Dizziness—Progesterone—uterine cancer	0.000304	0.00131	CcSEcCtD
Orlistat—Immune system disorder—Etoposide—uterine cancer	0.000299	0.00129	CcSEcCtD
Orlistat—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000299	0.00129	CcSEcCtD
Orlistat—Eczema—Epirubicin—uterine cancer	0.000299	0.00129	CcSEcCtD
Orlistat—Hepatic failure—Epirubicin—uterine cancer	0.000299	0.00129	CcSEcCtD
Orlistat—Mediastinal disorder—Etoposide—uterine cancer	0.000299	0.00129	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000296	0.00128	CcSEcCtD
Orlistat—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000295	0.00127	CcSEcCtD
Orlistat—Alopecia—Etoposide—uterine cancer	0.000293	0.00126	CcSEcCtD
Orlistat—Vomiting—Progesterone—uterine cancer	0.000293	0.00126	CcSEcCtD
Orlistat—Rash—Progesterone—uterine cancer	0.00029	0.00125	CcSEcCtD
Orlistat—Dermatitis—Progesterone—uterine cancer	0.00029	0.00125	CcSEcCtD
Orlistat—Headache—Progesterone—uterine cancer	0.000288	0.00124	CcSEcCtD
Orlistat—Increased appetite—Epirubicin—uterine cancer	0.000286	0.00123	CcSEcCtD
Orlistat—Diabetes mellitus—Doxorubicin—uterine cancer	0.000286	0.00123	CcSEcCtD
Orlistat—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000285	0.00123	CcSEcCtD
Orlistat—Menopausal symptoms—Epirubicin—uterine cancer	0.000285	0.00123	CcSEcCtD
Orlistat—Decreased appetite—Dactinomycin—uterine cancer	0.000283	0.00122	CcSEcCtD
Orlistat—Dysgeusia—Etoposide—uterine cancer	0.000282	0.00122	CcSEcCtD
Orlistat—Dermatitis bullous—Epirubicin—uterine cancer	0.000281	0.00121	CcSEcCtD
Orlistat—Fatigue—Dactinomycin—uterine cancer	0.00028	0.00121	CcSEcCtD
Orlistat—Back pain—Etoposide—uterine cancer	0.000279	0.0012	CcSEcCtD
Orlistat—Pain—Dactinomycin—uterine cancer	0.000278	0.0012	CcSEcCtD
Orlistat—Muscle spasms—Etoposide—uterine cancer	0.000277	0.0012	CcSEcCtD
Orlistat—Eczema—Doxorubicin—uterine cancer	0.000276	0.00119	CcSEcCtD
Orlistat—Hepatic failure—Doxorubicin—uterine cancer	0.000276	0.00119	CcSEcCtD
Orlistat—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000276	0.00119	CcSEcCtD
Orlistat—Hypoglycaemia—Epirubicin—uterine cancer	0.000275	0.00119	CcSEcCtD
Orlistat—Nausea—Progesterone—uterine cancer	0.000273	0.00118	CcSEcCtD
Orlistat—Osteoarthritis—Epirubicin—uterine cancer	0.000268	0.00116	CcSEcCtD
Orlistat—Feeling abnormal—Dactinomycin—uterine cancer	0.000268	0.00116	CcSEcCtD
Orlistat—Ill-defined disorder—Etoposide—uterine cancer	0.000268	0.00116	CcSEcCtD
Orlistat—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000266	0.00115	CcSEcCtD
Orlistat—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000265	0.00114	CcSEcCtD
Orlistat—Increased appetite—Doxorubicin—uterine cancer	0.000264	0.00114	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—uterine cancer	0.000263	0.00114	CcSEcCtD
Orlistat—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000263	0.00114	CcSEcCtD
Orlistat—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000263	0.00113	CcSEcCtD
Orlistat—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00113	CcSEcCtD
Orlistat—Malaise—Etoposide—uterine cancer	0.00026	0.00112	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—uterine cancer	0.00026	0.00112	CcSEcCtD
Orlistat—Vertigo—Etoposide—uterine cancer	0.000259	0.00112	CcSEcCtD
Orlistat—Abdominal pain—Dactinomycin—uterine cancer	0.000257	0.00111	CcSEcCtD
Orlistat—Body temperature increased—Dactinomycin—uterine cancer	0.000257	0.00111	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—uterine cancer	0.000255	0.0011	CcSEcCtD
Orlistat—Cough—Etoposide—uterine cancer	0.000252	0.00109	CcSEcCtD
Orlistat—Convulsion—Etoposide—uterine cancer	0.00025	0.00108	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—uterine cancer	0.000248	0.00107	CcSEcCtD
Orlistat—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000248	0.00107	CcSEcCtD
Orlistat—Dry skin—Epirubicin—uterine cancer	0.000246	0.00106	CcSEcCtD
Orlistat—Chest pain—Etoposide—uterine cancer	0.000246	0.00106	CcSEcCtD
Orlistat—Abdominal pain upper—Epirubicin—uterine cancer	0.000245	0.00106	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—uterine cancer	0.000244	0.00105	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000244	0.00105	CcSEcCtD
Orlistat—Discomfort—Etoposide—uterine cancer	0.000243	0.00105	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—uterine cancer	0.000243	0.00105	CcSEcCtD
Orlistat—Hypersensitivity—Dactinomycin—uterine cancer	0.00024	0.00103	CcSEcCtD
Orlistat—Gastritis—Epirubicin—uterine cancer	0.000238	0.00103	CcSEcCtD
Orlistat—Anaphylactic shock—Etoposide—uterine cancer	0.000235	0.00102	CcSEcCtD
Orlistat—Infection—Etoposide—uterine cancer	0.000234	0.00101	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—uterine cancer	0.000234	0.00101	CcSEcCtD
Orlistat—Asthenia—Dactinomycin—uterine cancer	0.000233	0.00101	CcSEcCtD
Orlistat—Influenza—Epirubicin—uterine cancer	0.000232	0.001	CcSEcCtD
Orlistat—Asthma—Epirubicin—uterine cancer	0.000232	0.001	CcSEcCtD
Orlistat—Skin disorder—Etoposide—uterine cancer	0.000229	0.000987	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—uterine cancer	0.000228	0.000983	CcSEcCtD
Orlistat—Hyperhidrosis—Etoposide—uterine cancer	0.000228	0.000982	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—uterine cancer	0.000228	0.000982	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—uterine cancer	0.000227	0.000979	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—uterine cancer	0.000226	0.000976	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—uterine cancer	0.000224	0.000969	CcSEcCtD
Orlistat—Diarrhoea—Dactinomycin—uterine cancer	0.000223	0.000961	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—uterine cancer	0.00022	0.000949	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—uterine cancer	0.000216	0.000933	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000216	0.000931	CcSEcCtD
Orlistat—Asthma—Doxorubicin—uterine cancer	0.000215	0.000927	CcSEcCtD
Orlistat—Influenza—Doxorubicin—uterine cancer	0.000215	0.000927	CcSEcCtD
Orlistat—Paraesthesia—Etoposide—uterine cancer	0.000211	0.000913	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—uterine cancer	0.000211	0.000909	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—uterine cancer	0.000207	0.000893	CcSEcCtD
Orlistat—Infestation—Epirubicin—uterine cancer	0.000207	0.000893	CcSEcCtD
Orlistat—Vomiting—Dactinomycin—uterine cancer	0.000207	0.000893	CcSEcCtD
Orlistat—Rash—Dactinomycin—uterine cancer	0.000205	0.000885	CcSEcCtD
Orlistat—Decreased appetite—Etoposide—uterine cancer	0.000205	0.000883	CcSEcCtD
Orlistat—Renal failure—Epirubicin—uterine cancer	0.000203	0.000878	CcSEcCtD
Orlistat—Gastrointestinal disorder—Etoposide—uterine cancer	0.000203	0.000877	CcSEcCtD
Orlistat—Fatigue—Etoposide—uterine cancer	0.000203	0.000876	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—uterine cancer	0.000203	0.000876	CcSEcCtD
Orlistat—Pain—Etoposide—uterine cancer	0.000201	0.000869	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—uterine cancer	0.000201	0.000868	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.0002	0.000861	CcSEcCtD
Orlistat—Hepatobiliary disease—Epirubicin—uterine cancer	0.000196	0.000845	CcSEcCtD
Orlistat—Sinusitis—Epirubicin—uterine cancer	0.000194	0.000838	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—uterine cancer	0.000194	0.000837	CcSEcCtD
Orlistat—Nausea—Dactinomycin—uterine cancer	0.000193	0.000834	CcSEcCtD
Orlistat—Gastrointestinal pain—Etoposide—uterine cancer	0.000193	0.000831	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—uterine cancer	0.000191	0.000826	CcSEcCtD
Orlistat—Infestation—Doxorubicin—uterine cancer	0.000191	0.000826	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—uterine cancer	0.000188	0.000812	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000188	0.00081	CcSEcCtD
Orlistat—Urticaria—Etoposide—uterine cancer	0.000187	0.000807	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—uterine cancer	0.000187	0.000806	CcSEcCtD
Orlistat—Abdominal pain—Etoposide—uterine cancer	0.000186	0.000803	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—uterine cancer	0.000186	0.000803	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—uterine cancer	0.000186	0.000803	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—uterine cancer	0.000186	0.000802	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—uterine cancer	0.000186	0.000802	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—uterine cancer	0.000184	0.000796	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—uterine cancer	0.000183	0.000792	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—uterine cancer	0.000183	0.00079	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—uterine cancer	0.000182	0.000786	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000181	0.000782	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—uterine cancer	0.00018	0.000775	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—uterine cancer	0.000173	0.000749	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—uterine cancer	0.000173	0.000746	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—uterine cancer	0.000172	0.000742	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—uterine cancer	0.000172	0.000742	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—uterine cancer	0.000171	0.000736	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—uterine cancer	0.00017	0.000733	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—uterine cancer	0.000169	0.000731	CcSEcCtD
Orlistat—Asthenia—Etoposide—uterine cancer	0.000169	0.000729	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—uterine cancer	0.000168	0.000727	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—uterine cancer	0.000168	0.000724	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—uterine cancer	0.000167	0.000723	CcSEcCtD
Orlistat—Pruritus—Etoposide—uterine cancer	0.000167	0.000719	CcSEcCtD
Orlistat—Alopecia—Epirubicin—uterine cancer	0.000164	0.000709	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—uterine cancer	0.000163	0.000702	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—uterine cancer	0.000162	0.000698	CcSEcCtD
Orlistat—Diarrhoea—Etoposide—uterine cancer	0.000161	0.000695	CcSEcCtD
Orlistat—Flatulence—Epirubicin—uterine cancer	0.000159	0.000688	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—uterine cancer	0.000158	0.000684	CcSEcCtD
Orlistat—Back pain—Epirubicin—uterine cancer	0.000156	0.000675	CcSEcCtD
Orlistat—Dizziness—Etoposide—uterine cancer	0.000156	0.000672	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—uterine cancer	0.000155	0.000671	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—uterine cancer	0.000155	0.00067	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—uterine cancer	0.000155	0.000669	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—uterine cancer	0.000152	0.000658	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—uterine cancer	0.000152	0.000656	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—uterine cancer	0.000151	0.00065	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—uterine cancer	0.00015	0.000648	CcSEcCtD
Orlistat—Vomiting—Etoposide—uterine cancer	0.00015	0.000646	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—uterine cancer	0.00015	0.000646	CcSEcCtD
Orlistat—Rash—Etoposide—uterine cancer	0.000148	0.000641	CcSEcCtD
Orlistat—Dermatitis—Etoposide—uterine cancer	0.000148	0.00064	CcSEcCtD
Orlistat—Headache—Etoposide—uterine cancer	0.000147	0.000637	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—uterine cancer	0.000147	0.000636	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—uterine cancer	0.000147	0.000632	CcSEcCtD
Orlistat—Malaise—Epirubicin—uterine cancer	0.000146	0.000629	CcSEcCtD
Orlistat—Vertigo—Epirubicin—uterine cancer	0.000145	0.000627	CcSEcCtD
Orlistat—Back pain—Doxorubicin—uterine cancer	0.000145	0.000625	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—uterine cancer	0.000144	0.000621	CcSEcCtD
Orlistat—Palpitations—Epirubicin—uterine cancer	0.000143	0.000617	CcSEcCtD
Orlistat—Cough—Epirubicin—uterine cancer	0.000141	0.000609	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—uterine cancer	0.000141	0.000609	CcSEcCtD
Orlistat—Convulsion—Epirubicin—uterine cancer	0.00014	0.000605	CcSEcCtD
Orlistat—Nausea—Etoposide—uterine cancer	0.00014	0.000604	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—uterine cancer	0.000139	0.000599	CcSEcCtD
Orlistat—Myalgia—Epirubicin—uterine cancer	0.000138	0.000594	CcSEcCtD
Orlistat—Chest pain—Epirubicin—uterine cancer	0.000138	0.000594	CcSEcCtD
Orlistat—Anxiety—Epirubicin—uterine cancer	0.000137	0.000592	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000137	0.00059	CcSEcCtD
Orlistat—Discomfort—Epirubicin—uterine cancer	0.000136	0.000587	CcSEcCtD
Orlistat—Malaise—Doxorubicin—uterine cancer	0.000135	0.000582	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—uterine cancer	0.000135	0.000581	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—uterine cancer	0.000134	0.00058	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—uterine cancer	0.000132	0.000571	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—uterine cancer	0.000132	0.00057	CcSEcCtD
Orlistat—Oedema—Epirubicin—uterine cancer	0.000132	0.00057	CcSEcCtD
Orlistat—Infection—Epirubicin—uterine cancer	0.000131	0.000566	CcSEcCtD
Orlistat—Cough—Doxorubicin—uterine cancer	0.000131	0.000564	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—uterine cancer	0.00013	0.00056	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—uterine cancer	0.000129	0.000559	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—uterine cancer	0.000128	0.000553	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—uterine cancer	0.000128	0.000551	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—uterine cancer	0.000127	0.00055	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—uterine cancer	0.000127	0.00055	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—uterine cancer	0.000127	0.000548	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000126	0.000546	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—uterine cancer	0.000126	0.000543	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—uterine cancer	0.000125	0.000538	CcSEcCtD
Orlistat—Oedema—Doxorubicin—uterine cancer	0.000122	0.000527	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—uterine cancer	0.000122	0.000527	CcSEcCtD
Orlistat—Infection—Doxorubicin—uterine cancer	0.000121	0.000524	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—IRF1—uterine cancer	0.000121	0.00116	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—KRAS—uterine cancer	0.000121	0.00116	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—KRAS—uterine cancer	0.000121	0.00116	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—AKT1—uterine cancer	0.000121	0.00116	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NDUFB11—uterine cancer	0.00012	0.00115	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SRD5A2—uterine cancer	0.00012	0.00115	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.00012	0.00115	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00012	0.000519	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—uterine cancer	0.00012	0.000517	CcSEcCtD
Orlistat—Insomnia—Epirubicin—uterine cancer	0.000119	0.000515	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SOCS3—uterine cancer	0.000119	0.00114	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SOCS3—uterine cancer	0.000119	0.00114	CbGpPWpGaD
Orlistat—Skin disorder—Doxorubicin—uterine cancer	0.000119	0.000512	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.000119	0.00114	CbGpPWpGaD
Orlistat—Paraesthesia—Epirubicin—uterine cancer	0.000118	0.000512	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—uterine cancer	0.000118	0.00051	CcSEcCtD
Orlistat—PNLIP—Disease—FGFR2—uterine cancer	0.000118	0.00113	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.000118	0.00113	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000117	0.00112	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—AKT1—uterine cancer	0.000116	0.00111	CbGpPWpGaD
Orlistat—Dyspepsia—Epirubicin—uterine cancer	0.000116	0.000501	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—uterine cancer	0.000115	0.000495	CcSEcCtD
Orlistat—FASN—Metabolism—AKR1C3—uterine cancer	0.000115	0.0011	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN2B—uterine cancer	0.000114	0.0011	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN2B—uterine cancer	0.000114	0.0011	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000114	0.000492	CcSEcCtD
Orlistat—Fatigue—Epirubicin—uterine cancer	0.000114	0.000491	CcSEcCtD
Orlistat—PNLIP—Disease—MTHFR—uterine cancer	0.000113	0.00109	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.000113	0.00108	CbGpPWpGaD
Orlistat—Pain—Epirubicin—uterine cancer	0.000113	0.000487	CcSEcCtD
Orlistat—PLA2G4A—Phospholipid metabolism—PTEN—uterine cancer	0.000112	0.00107	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000111	0.00048	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—IGF1R—uterine cancer	0.000111	0.00106	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IGF1R—uterine cancer	0.000111	0.00106	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—PIK3CA—uterine cancer	0.000111	0.00106	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—PIK3CA—uterine cancer	0.000111	0.00106	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.00011	0.00106	CbGpPWpGaD
Orlistat—Insomnia—Doxorubicin—uterine cancer	0.00011	0.000477	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—CXCL8—uterine cancer	0.00011	0.00106	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CXCL8—uterine cancer	0.00011	0.00106	CbGpPWpGaD
Orlistat—Paraesthesia—Doxorubicin—uterine cancer	0.00011	0.000473	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—uterine cancer	0.000109	0.000469	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—NRAS—uterine cancer	0.000108	0.00103	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Epirubicin—uterine cancer	0.000108	0.000466	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—uterine cancer	0.000107	0.000464	CcSEcCtD
Orlistat—DAGLB—Hemostasis—TP53—uterine cancer	0.000107	0.00103	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—uterine cancer	0.000107	0.00103	CbGpPWpGaD
Orlistat—Decreased appetite—Doxorubicin—uterine cancer	0.000106	0.000458	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—STK11—uterine cancer	0.000106	0.00101	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000105	0.000455	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—uterine cancer	0.000105	0.000454	CcSEcCtD
Orlistat—Urticaria—Epirubicin—uterine cancer	0.000105	0.000453	CcSEcCtD
Orlistat—Pain—Doxorubicin—uterine cancer	0.000104	0.000451	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—uterine cancer	0.000104	0.00045	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—uterine cancer	0.000104	0.00045	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—SMAD3—uterine cancer	0.000104	0.001	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SMAD3—uterine cancer	0.000104	0.001	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—uterine cancer	0.000103	0.000983	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—uterine cancer	0.000103	0.000983	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000101	0.000969	CbGpPWpGaD
Orlistat—Feeling abnormal—Doxorubicin—uterine cancer	0.000101	0.000434	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—CXCL8—uterine cancer	0.0001	0.000961	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCL8—uterine cancer	0.0001	0.000961	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Doxorubicin—uterine cancer	9.98e-05	0.000431	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—FGFR2—uterine cancer	9.95e-05	0.000954	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FGFR2—uterine cancer	9.95e-05	0.000954	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SOCS3—uterine cancer	9.89e-05	0.000948	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	9.88e-05	0.000948	CbGpPWpGaD
Orlistat—Hypersensitivity—Epirubicin—uterine cancer	9.72e-05	0.00042	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—uterine cancer	9.7e-05	0.000419	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—uterine cancer	9.65e-05	0.000417	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—uterine cancer	9.65e-05	0.000417	CcSEcCtD
Orlistat—FASN—Disease—CDKN2B—uterine cancer	9.56e-05	0.000917	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—MTHFR—uterine cancer	9.49e-05	0.00091	CbGpPWpGaD
Orlistat—Asthenia—Epirubicin—uterine cancer	9.47e-05	0.000409	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CDKN2B—uterine cancer	9.46e-05	0.000907	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	9.36e-05	0.000897	CbGpPWpGaD
Orlistat—Pruritus—Epirubicin—uterine cancer	9.34e-05	0.000403	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—KRAS—uterine cancer	9.29e-05	0.000891	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF1R—uterine cancer	9.19e-05	0.000881	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—AKT1—uterine cancer	9.05e-05	0.000868	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—AKT1—uterine cancer	9.05e-05	0.000868	CbGpPWpGaD
Orlistat—Diarrhoea—Epirubicin—uterine cancer	9.03e-05	0.00039	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—uterine cancer	9e-05	0.000388	CcSEcCtD
Orlistat—FASN—Metabolism—CYP19A1—uterine cancer	8.93e-05	0.000857	CbGpPWpGaD
Orlistat—FASN—Metabolism—STK11—uterine cancer	8.93e-05	0.000857	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	8.84e-05	0.000848	CbGpPWpGaD
Orlistat—Asthenia—Doxorubicin—uterine cancer	8.76e-05	0.000378	CcSEcCtD
Orlistat—FASN—Disease—SMAD3—uterine cancer	8.73e-05	0.000837	CbGpPWpGaD
Orlistat—Dizziness—Epirubicin—uterine cancer	8.73e-05	0.000377	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—AKR1B1—uterine cancer	8.71e-05	0.000835	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—STAR—uterine cancer	8.71e-05	0.000835	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SMAD3—uterine cancer	8.64e-05	0.000829	CbGpPWpGaD
Orlistat—Pruritus—Doxorubicin—uterine cancer	8.64e-05	0.000373	CcSEcCtD
Orlistat—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	8.63e-05	0.000828	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	8.62e-05	0.000826	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	8.61e-05	0.000825	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—uterine cancer	8.53e-05	0.000818	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ESR1—uterine cancer	8.51e-05	0.000816	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ESR1—uterine cancer	8.51e-05	0.000816	CbGpPWpGaD
Orlistat—Vomiting—Epirubicin—uterine cancer	8.39e-05	0.000362	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.39e-05	0.000804	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.36e-05	0.000802	CbGpPWpGaD
Orlistat—Diarrhoea—Doxorubicin—uterine cancer	8.35e-05	0.000361	CcSEcCtD
Orlistat—FASN—Disease—FGFR2—uterine cancer	8.33e-05	0.000798	CbGpPWpGaD
Orlistat—Rash—Epirubicin—uterine cancer	8.32e-05	0.000359	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—uterine cancer	8.31e-05	0.000359	CcSEcCtD
Orlistat—Headache—Epirubicin—uterine cancer	8.27e-05	0.000357	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—FGFR2—uterine cancer	8.24e-05	0.00079	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	8.22e-05	0.000788	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—uterine cancer	8.07e-05	0.000349	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—NRAS—uterine cancer	8.04e-05	0.000771	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NRAS—uterine cancer	8.04e-05	0.000771	CbGpPWpGaD
Orlistat—FASN—Disease—MTHFR—uterine cancer	8.02e-05	0.000769	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8e-05	0.000767	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—uterine cancer	7.9e-05	0.000757	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PIK3CA—uterine cancer	7.88e-05	0.000756	CbGpPWpGaD
Orlistat—Nausea—Epirubicin—uterine cancer	7.84e-05	0.000338	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—AKR1B10—uterine cancer	7.83e-05	0.000751	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	7.78e-05	0.000746	CbGpPWpGaD
Orlistat—Vomiting—Doxorubicin—uterine cancer	7.76e-05	0.000335	CcSEcCtD
Orlistat—Rash—Doxorubicin—uterine cancer	7.7e-05	0.000332	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—uterine cancer	7.69e-05	0.000332	CcSEcCtD
Orlistat—Headache—Doxorubicin—uterine cancer	7.65e-05	0.00033	CcSEcCtD
Orlistat—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	7.58e-05	0.000727	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCL2—uterine cancer	7.49e-05	0.000718	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL2—uterine cancer	7.49e-05	0.000718	CbGpPWpGaD
Orlistat—PNLIP—Disease—ERBB2—uterine cancer	7.39e-05	0.000709	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—uterine cancer	7.25e-05	0.000313	CcSEcCtD
Orlistat—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	7.14e-05	0.000684	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ESR1—uterine cancer	7.05e-05	0.000676	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	7.04e-05	0.000675	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PIK3CA—uterine cancer	7e-05	0.000672	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PIK3CA—uterine cancer	7e-05	0.000672	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	6.93e-05	0.000664	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—uterine cancer	6.92e-05	0.000664	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—uterine cancer	6.92e-05	0.000664	CbGpPWpGaD
Orlistat—PNLIP—Disease—CDKN1B—uterine cancer	6.84e-05	0.000656	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POLD1—uterine cancer	6.83e-05	0.000655	CbGpPWpGaD
Orlistat—FASN—Metabolism—MTHFR—uterine cancer	6.71e-05	0.000644	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	6.65e-05	0.000637	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	6.62e-05	0.000634	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RNF43—uterine cancer	6.49e-05	0.000622	CbGpPWpGaD
Orlistat—PNLIP—Disease—CTNNB1—uterine cancer	6.47e-05	0.00062	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKR1C1—uterine cancer	6.39e-05	0.000613	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PIK3CA—uterine cancer	6.36e-05	0.00061	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—uterine cancer	6.36e-05	0.00061	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—uterine cancer	6.3e-05	0.000604	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ERBB2—uterine cancer	6.25e-05	0.000599	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—uterine cancer	6.25e-05	0.000599	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL2—uterine cancer	6.21e-05	0.000595	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	6.08e-05	0.000583	CbGpPWpGaD
Orlistat—PNLIP—Disease—EP300—uterine cancer	6.01e-05	0.000576	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INHBA—uterine cancer	5.94e-05	0.000569	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL8—uterine cancer	5.92e-05	0.000568	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—uterine cancer	5.92e-05	0.000568	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.92e-05	0.000567	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—uterine cancer	5.88e-05	0.000564	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—uterine cancer	5.88e-05	0.000564	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	5.88e-05	0.000564	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1B—uterine cancer	5.78e-05	0.000555	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1B—uterine cancer	5.78e-05	0.000555	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—uterine cancer	5.72e-05	0.000549	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—uterine cancer	5.72e-05	0.000549	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RRM2—uterine cancer	5.7e-05	0.000546	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRAS—uterine cancer	5.62e-05	0.000539	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—DCN—uterine cancer	5.53e-05	0.00053	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—uterine cancer	5.46e-05	0.000524	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—uterine cancer	5.46e-05	0.000524	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	5.41e-05	0.000519	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKR1C1—uterine cancer	5.34e-05	0.000512	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—uterine cancer	5.33e-05	0.000511	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—uterine cancer	5.33e-05	0.000511	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—uterine cancer	5.28e-05	0.000506	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	5.25e-05	0.000503	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—uterine cancer	5.23e-05	0.000501	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP11A1—uterine cancer	5.21e-05	0.0005	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—uterine cancer	5.2e-05	0.000498	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—uterine cancer	5.2e-05	0.000498	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	5.18e-05	0.000496	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—uterine cancer	5.18e-05	0.000496	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EP300—uterine cancer	5.08e-05	0.000487	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EP300—uterine cancer	5.08e-05	0.000487	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—EP300—uterine cancer	5.03e-05	0.000483	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.97e-05	0.000476	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKR1C3—uterine cancer	4.92e-05	0.000472	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL8—uterine cancer	4.91e-05	0.000471	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1B—uterine cancer	4.84e-05	0.000464	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—uterine cancer	4.84e-05	0.000464	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—uterine cancer	4.81e-05	0.000461	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—uterine cancer	4.81e-05	0.000461	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1B—uterine cancer	4.79e-05	0.00046	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—uterine cancer	4.75e-05	0.000456	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—uterine cancer	4.75e-05	0.000456	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—uterine cancer	4.57e-05	0.000439	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—uterine cancer	4.53e-05	0.000434	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—uterine cancer	4.46e-05	0.000428	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—uterine cancer	4.45e-05	0.000426	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—uterine cancer	4.42e-05	0.000424	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—uterine cancer	4.41e-05	0.000423	CbGpPWpGaD
Orlistat—FASN—Disease—EP300—uterine cancer	4.25e-05	0.000408	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EP300—uterine cancer	4.21e-05	0.000404	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKR1C3—uterine cancer	4.11e-05	0.000395	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—uterine cancer	4.11e-05	0.000394	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—uterine cancer	4.09e-05	0.000392	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—uterine cancer	4.09e-05	0.000392	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PGR—uterine cancer	4.01e-05	0.000384	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—uterine cancer	3.99e-05	0.000382	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—uterine cancer	3.98e-05	0.000381	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—uterine cancer	3.94e-05	0.000378	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP19A1—uterine cancer	3.83e-05	0.000368	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—STK11—uterine cancer	3.83e-05	0.000368	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—YWHAE—uterine cancer	3.82e-05	0.000367	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EP300—uterine cancer	3.77e-05	0.000361	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—uterine cancer	3.76e-05	0.00036	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—uterine cancer	3.76e-05	0.00036	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—uterine cancer	3.73e-05	0.000358	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—uterine cancer	3.72e-05	0.000357	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FBXW7—uterine cancer	3.67e-05	0.000352	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—uterine cancer	3.64e-05	0.000349	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—uterine cancer	3.64e-05	0.000349	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—uterine cancer	3.63e-05	0.000348	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.6e-05	0.000345	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—uterine cancer	3.57e-05	0.000342	CbGpPWpGaD
Orlistat—FASN—Metabolism—EP300—uterine cancer	3.56e-05	0.000341	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—uterine cancer	3.53e-05	0.000338	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—uterine cancer	3.48e-05	0.000333	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—uterine cancer	3.48e-05	0.000333	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.43e-05	0.000329	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—uterine cancer	3.42e-05	0.000328	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—uterine cancer	3.39e-05	0.000325	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STK11—uterine cancer	3.21e-05	0.000307	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL2—uterine cancer	3.19e-05	0.000306	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—uterine cancer	3.15e-05	0.000302	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—uterine cancer	3.11e-05	0.000299	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—uterine cancer	3.07e-05	0.000294	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—uterine cancer	3.07e-05	0.000294	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—uterine cancer	3.04e-05	0.000292	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—uterine cancer	3.04e-05	0.000291	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—uterine cancer	3.01e-05	0.000289	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SOCS3—uterine cancer	3e-05	0.000288	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—uterine cancer	2.91e-05	0.000279	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—uterine cancer	2.88e-05	0.000276	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—uterine cancer	2.88e-05	0.000276	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN2B—uterine cancer	2.87e-05	0.000276	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.82e-05	0.00027	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.82e-05	0.00027	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—uterine cancer	2.79e-05	0.000268	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—uterine cancer	2.79e-05	0.000267	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—uterine cancer	2.7e-05	0.000259	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—uterine cancer	2.63e-05	0.000253	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMAD3—uterine cancer	2.62e-05	0.000252	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—uterine cancer	2.58e-05	0.000247	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—uterine cancer	2.57e-05	0.000246	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—uterine cancer	2.54e-05	0.000244	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.54e-05	0.000243	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—uterine cancer	2.52e-05	0.000242	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR2—uterine cancer	2.5e-05	0.00024	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—uterine cancer	2.28e-05	0.000218	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—uterine cancer	2.15e-05	0.000206	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—uterine cancer	2.14e-05	0.000205	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.04e-05	0.000196	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STAR—uterine cancer	2.04e-05	0.000196	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—uterine cancer	2.02e-05	0.000194	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL2—uterine cancer	1.88e-05	0.000181	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—uterine cancer	1.74e-05	0.000167	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—uterine cancer	1.6e-05	0.000154	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POLD1—uterine cancer	1.6e-05	0.000153	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—uterine cancer	1.6e-05	0.000153	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—uterine cancer	1.57e-05	0.000151	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—EP300—uterine cancer	1.53e-05	0.000147	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.5e-05	0.000144	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—uterine cancer	1.49e-05	0.000143	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—uterine cancer	1.48e-05	0.000142	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1B—uterine cancer	1.46e-05	0.00014	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—uterine cancer	1.37e-05	0.000132	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—uterine cancer	1.34e-05	0.000128	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RRM2—uterine cancer	1.33e-05	0.000128	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—uterine cancer	1.31e-05	0.000125	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—DCN—uterine cancer	1.3e-05	0.000124	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EP300—uterine cancer	1.28e-05	0.000123	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.22e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—uterine cancer	1.21e-05	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—uterine cancer	1.2e-05	0.000115	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.15e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—uterine cancer	1.13e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—uterine cancer	1.03e-05	9.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—uterine cancer	9.45e-06	9.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—uterine cancer	9.24e-06	8.86e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—uterine cancer	9.15e-06	8.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP19A1—uterine cancer	8.98e-06	8.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STK11—uterine cancer	8.98e-06	8.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—uterine cancer	8.75e-06	8.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—uterine cancer	7.72e-06	7.4e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—uterine cancer	6.75e-06	6.47e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—uterine cancer	3.75e-06	3.6e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EP300—uterine cancer	3.58e-06	3.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.65e-06	2.54e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—uterine cancer	2.16e-06	2.07e-05	CbGpPWpGaD
